Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation

被引：50

作者：

Kessler, Tobias ^{[1
,2
]}

Sahm, Felix ^{[3
,4
]}

Sadik, Ahmed ^{[5
]}

Stichel, Damian ^{[3
,4
]}

Hertenstein, Anne ^{[1
,2
]}

Reifenberger, Guido ^{[6
]}

Zacher, Angela ^{[6
]}

Sabel, Michael ^{[7
]}

Tabatabai, Ghazaleh ^{[8
,9
,10
]}

Steinbach, Joachim ^{[11
]}

Sure, Ulrich ^{[12
]}

Krex, Dietmar ^{[13
]}

Grosu, Anca-L ^{[14
,15
,16
]}

Bewerunge-Hudler, Melanie ^{[17
]}

Jones, David ^{[18
]}

Pfister, Stefan M. ^{[18
,19
,20
]}

Weller, Michael ^{[21
]}

Opitz, Christiane ^{[2
,5
]}

Bendszus, Martin ^{[22
]}

von Deimling, Andreas ^{[3
,4
]}

Platten, Michael ^{[2
,23
,24
]}

Wick, Wolfgang ^{[1
,2
]}

机构：

[1] German Canc Res Ctr, German Canc Consortium DKTK, Clin Cooperat Unit Neurooncol, Heidelberg, Germany

[2] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany

[3] DKFZ, DKTK, Clin Cooperat Unit Neuropathol, Heidelberg, Germany

[4] Heidelberg Univ Hosp, Dept Neuropathol, Heidelberg, Germany

[5] DKFZ, Brain Tumor Metab, Heidelberg, Germany

[6] Heinrich Heine Univ Hosp, Dept Neuropathol, Dusseldorf, Germany

[7] Heinrich Heine Univ Hosp, Dept Neurosurg, Dusseldorf, Germany

[8] Eberhard Karls Univ Tubingen, Interdisciplinary Div Neurooncol, Dept Vasc Neurol & Neurosurg,DKFZ Partner Site Tu, Hertie Inst Clin Brain Res,Univ Hosp Tubingen,DKT, Tubingen, Germany

[9] Eberhard Karls Univ Tubingen, Ctr Personalized Med, Tubingen, Germany

[10] Comprehens Canc Ctr Tubingen Stuttgart, Ctr CNS Tumors, Tubingen, Germany

[11] Goethe Univ Hosp, Dr Senckenberg Inst Neurooncol, Frankfurt, Germany

[12] Univ Duisburg Essen, Dept Neurosurg, Essen, Germany

[13] Univ Klinikum Carl Gustav Carus, Dept Neurosurg, Dresden, Germany

[14] Univ Freiburg, Fac Med, Med Ctr Univ Freiburg, Dept Radiat Oncol, Freiburg, Germany

[15] DKTK Partner Site Freiburg, Freiburg, Germany

[16] DKFZ Heidelberg, Freiburg, Germany

[17] DKFZ, Microarray Unit, Genom & Prote Core Facil, Heidelberg, Germany

[18] DKFZ, DKTK, Div Pediat Neurooncol, Heidelberg, Germany

[19] Heidelberg Univ Hosp, Dept Pediat Oncol Haematol & Immunol, Heidelberg, Germany

[20] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[21] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[22] Heidelberg Univ Hosp, Dept Neuroradiol, Heidelberg, Germany

[23] DKFZ, DKTK, Clin Cooperat Unit Neuroimmunol & Brain Tumor Imm, Heidelberg, Germany

[24] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Neurol, Mannheim, Germany

来源：

NEURO-ONCOLOGY | 2018年 / 20卷 / 03期

关键词：

glioblastoma biomarker; NF kappa B; O-6-methylguanine-DNA-methyltransferase (MGMT); PDGFRA; TERT; NEWLY-DIAGNOSED GLIOBLASTOMA; PHASE-II; TEMOZOLOMIDE; GLIOMA; GENE; CELLS; RADIOTHERAPY; COMBINATION; TRIAL; METHYLTRANSFERASE;

D O I：

10.1093/neuonc/nox160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma. We investigated whether this marker furthermore defines a molecularly distinct tumor subtype with clinically different outcome. Methods. We analyzed copy number variation (CNV) and methylation profiles of 1095 primary and 92 progressive isocitrate dehydrogenase wildtype glioblastomas, including paired samples from 49 patients. DNA mutation data from 182 glioblastoma samples of The Cancer Genome Atlas (TCGA) and RNA expression from 107 TCGA and 55 Chinese Glioma Genome Atlas samples were analyzed. Results. Among untreated glioblastomas, MGMT promoter methylated (mMGMT) and unmethylated (uMGMT) tumors did not show different CNV or specific gene mutations, but a higher mutation count in mMGMT tumors. We identified 3 methylation clusters. Cluster 1 showed the highest average methylation and was enriched for mMGMT tumors. Seventeen genes including gastrulation brain homeobox 2 (GBX2) were found to be hypermethylated and downregulated on the mRNA level in mMGMT tumors. In progressive glioblastomas, platelet derived growth factor receptor alpha (PDGFRA) and GLI2 amplifications were enriched in mMGMT tumors. Methylated MGMT tumors gain PDGFRA amplification of PDGFRA, whereas uMGMT tumors with amplified PDGFRA frequently lose this amplification upon progression. Glioblastoma patients surviving <6 months and with mMGMT harbored less frequent epidermal growth factor receptor (EGFR) amplifications, more frequent TP53 mutations, and a higher tumor necrosis factor-nuclear factor-kappaB (TNF-NF kappa B) pathway activation compared with patients surviving >12 months. Conclusions. MGMT promoter methylation status does not define a molecularly distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT glioblastomas and mMGMT tumors of patients with short survival tend to have more unfavorable molecular profiles.

引用

页码：367 / 379

页数：13

共 50 条

[21] The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients
Torre, Matthew
Wen, Patrick Y.
Iorgulescu, J. Bryan
NEURO-ONCOLOGY PRACTICE, 2023, 10 (02) : 126 - 131
[22] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
Lombardi, Giuseppe
Giunco, Silvia
Cavallin, Francesco
Angelini, Chiara
Caccese, Mario
Cerretti, Giulia
De Bonis, Pasquale
De Rossi, Anita
Zagonel, Vittorina
NEURO-ONCOLOGY, 2021, 23 : 15 - 15
[23] MGMT promoter methylation in Peruvian patients with glioblastoma
Belmar-Lopez, Carolina
Castaneda, Carlos A.
Castillo, Miluska
Garcia-Corrochano, Pamela
Orrego, Enrique
Melendez, Barbara
Casavilca, Sandro
Flores, Claudio
Orrego, Enrique
ECANCERMEDICALSCIENCE, 2018, 12
[24] Impact of MGMT promoter methylation in glioblastoma of the elderly
Weller, M.
Hentschel, B.
Felsberg, J.
Schackert, G.
Simon, M.
Schnell, O.
Westphal, M.
Wick, W.
Pietsch, T.
Loeffler, M.
Reifenberger, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[25] Racial/ethnic disparities in healthcare utilization, post-operative outcomes, and overall survival for IDH-wildtype glioblastoma stratifying by MGMT promoter methylation status
Zhu, Ping
Chen, Clark C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
Alnahhas, Iyad
LaHaye, Stephanie
Giglio, Pierre
Mardis, Elaine
Puduvalli, Vinay
NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
[27] Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
Kim, Moonsik
Yoo, Jihwan
Chang, Jong Hee
Kim, Se Hoon
ANTICANCER RESEARCH, 2022, 42 (01) : 335 - 341
[28] Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
Weller, M.
Gramatzki, D.
Felsberg, J.
Hentschel, B.
Wolter, M.
Schackert, G.
Westphal, M.
Regli, L.
Thon, N.
Tatagiba, M.
Wick, W.
Schlegel, U.
Krex, D.
Roth, P.
Rushing, E.
Pietsch, T.
von Deimling, A.
Sabel, M.
Loeffler, M.
Reifenberger, G.
ANNALS OF ONCOLOGY, 2020, 31 : S396 - S396
[29] Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, Guido
Hentschel, Bettina
Felsberg, Joerg
Schackert, Gabriele
Simon, Matthias
Schnell, Oliver
Westphal, Manfred
Wick, Wolfgang
Pietsch, Torsten
Loeffler, Markus
Weller, Michael
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (06) : 1342 - 1350
[30] MGMT promoter methylation status and expression in human glioblastoma
Rodriguez, FJ
Thibodeau, SN
Jenkins, RB
Schowalter, KV
O'Neill, BP
James, CD
Giannini, C
MODERN PATHOLOGY, 2006, 19 : 287A - 287A

← 1 2 3 4 5 →